Answers are grounded in this paper and cite their sources.
Premature ejaculation (PE) is one of the most common male sexual dysfunctions, with a lifetime prevalence of ~20% and only 9% of affected men seeking medical attention.1 Diagnostic definitions from the DSM-5 and the International Society for Sexual Medicine describe PE as ejaculation occurring consistently within ~1 min for lifelong PE or ~3 min for acquired PE, accompanied by an inability to delay ejaculation and significant personal or interpersonal distress based on established clinical guidelines.2 The condition has a substantial psychosocial impact: men report reduced self-esteem and increased distress, while partners experience sexual dissatisfaction, frustration, and relationship strain. Despite its prevalence and burden, available treatment options are limited. Off-label daily selective serotonin reuptake inhibitors (SSRIs) and on-demand dapoxetine have high discontinuation rates, are widely used but only modestly effective, are associated with undesirable side effects, and have low long-term adherence. Notably, there is still no US-approved medication for PE. These limitations highlight the need for new pharmacological approaches. The para-chloroamphetamine (PCA)–induced ejaculation model is a well-established method for studying ejaculatory physiology and pharmacological modulation in rats.3 PCA is an amphetamine derivative that induces release of serotonin and catecholamines, reliably triggering ejaculation in conscious and anaesthetized rodents.3 Ejaculation is a coordinated spinal and supraspinal reflex consisting of two phases: emission, involving seminal vesicle contractions and increases in seminal vesicle pressure (SVP), and expulsion, mediated by rhythmic contractions of the bulbospongiosus (BS) muscles. SVP elevations and BS electromyographic (EMG) bursts therefore serve as established physiological markers of ejaculatory events in this model. The present study investigated the effect of KH-001 on PCA-induced ejaculation. KH-001 is a small molecule derived from a natural product screen for serotonergic modulators and subsequently selected for development based on its high affinity and selectivity for the serotonin transporter (SERT), a key regulator of inhibitory control over the ejaculatory reflex.4 KH-001 is a highly purified botanical mesembrine derivative. In uptake assays, KH-001 produced 99.2% inhibition of SERT at 10 μM, with IC50 values of 6.6 nM (human) and 2.7 nM (rat), demonstrating strong potency with Hill slopes near unity. In ex vivo rat cortical synaptosomes, KH-001 inhibited serotonin reuptake with an IC50 of 13 nM (Ki = 12 nM), closely aligning with fluoxetine. Off-target effects across a broad receptor and enzyme panel were limited, although notable secondary inhibition of PDE4D2 (87.7%) and PDE4B1 (IC50 = 1.2 μM) was observed, suggesting a primarily serotonergic mechanism with possible secondary PDE4-related effects. By enhancing serotonergic tone within central circuits governing ejaculation, KH-001 is hypothesized to increase ejaculatory latency and disrupt the neuromuscular coordination underlying expulsion. Adult male Wistar rats were acclimated and randomized into treatment groups with comparable body weights (364 ± 4 g). Animals received intraperitoneal injections of vehicle or KH-001 at doses of 20 μg/kg, 200 μg/kg, 2 mg/kg, 10 mg/kg, or 20 mg/kg 1 h before ejaculation assessment. PCA (5 mg/kg, i.p.) was then administered to induce ejaculation following established protocols. During a 30-min post-PCA observation period, seminal plug expulsion, SVP increases, and BS-EMG bursts were recorded as indicators of ejaculatory activity. Ejaculation was defined by the presence of a seminal plug accompanied by characteristic SVP elevation and synchronized BS muscle contractions. All procedures were performed in accordance with the legislation on the use of laboratory animals (NIH Publication No 85-23, revised 1996) and animal care regulations in force in France as of 1988 (Authorization from competent French ministry of agriculture- agreement no. B78-423-1, July 2017). KH-001 significantly increased latency to first ejaculation in a dose-dependent manner (Supplemental Table S1; Supplemental Figure S1). The minimum effective dose was 200 μg/kg (P < 0.01 vs. vehicle), and no rats in the 20 mg/kg group ejaculated during the evaluation window. A reduction in the proportion of ejaculating animals was also observed at 2 mg/kg and 10 mg/kg. KH-001 reduced SVP amplitude but did not affect BS-EMG activity (Supplemental Tables S2 and S3), suggesting a selective effect on seminal vesicle contractions. These findings demonstrate that KH-001 delays ejaculation in the PCA model and modulates physiological markers associated with the emission phase of ejaculation. A general methodological consideration of the current study is that the latency of ejaculation is computed only in rats that showed at least one ejaculation within the predefined 30-min observation window and thus the statistical significance is dependent on the number of the ejaculating rats. Therefore, in treatment groups where none of the rats ejaculated, the latency of ejaculation could not be computed. To overcome this consideration, Kaplan–Meier analysis was used (Supplemental Figure S1). Since KH-001 significantly increased latency to first ejaculation, these data suggest that KH-001 may represent a potential development candidate for the treatment of PE. KH-001 may delay ejaculation by enhancing serotonergic signaling through high-affinity inhibition of SERT, a mechanism known to elevate synaptic 5-HT levels and prolong ejaculatory latency via activation of inhibitory 5-HT receptors such as 5-HT1A and 5-HT2C. Additionally, its PDE4 inhibitory activity may reduce excitatory neurotransmission and spinal reflex sensitivity, further contributing to delayed ejaculatory response through suppression of central and peripheral excitability. Further work is required, including pharmacokinetics, absorption, distribution, metabolism, and excretion (ADME), toxicology and safety studies to understand the relationship between pharmacokinetics and pharmacodynamics of the tested compounds and the potential of KH-001 as a candidate for the treatment of PE. The work was financed by Kanna Health Ltd (t/a Kadence Bio). TP, NG and RP are shareholders of Kanna Health Ltd. Meeting Presentation: Work was presented at the European Society for Sexual Medicine, https://doi.org/10.1093/jsxmed/qdad062.002
No takes yet. Share an insight, caveat, or question.
Pfeiffer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: